Lisata Therapeutics News

Express News | Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Reuters08:00 ET

Express News | Lisata Therapeutics Inc Files for Mixed Shelf Offering of up to $150 Mln- SEC Filing

Reuters16:04 ET

Express News | HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

BenzingaApr 25 13:17 ET

Lisata Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 455.91% HC Wainwright & Co. → $15 Reiterates Buy → Buy 03/01/2024 455.91% HC Wainwright & Co. →

BenzingaApr 25 13:16 ET

Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)

TipRanksApr 25 11:30 ET

Lisata Therapeutics Advances Lead Asset LSTA1 for Treatment of Advanced Solid Tumors

Yahoo FinanceApr 23 10:48 ET

Express News | Lisata Therapeutics And Qilu Pharmaceutical Announce First Patient Treated In Qilu's Phase 2 Trial Of LSTA1 In Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Moomoo 24/7Apr 23 07:32 ET

Express News | Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of Lsta1 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Moomoo 24/7Apr 23 07:30 ET

Lisata Therapeutics Elevates James Nisco to Senior VP Finance

TipRanksApr 17 16:12 ET

Express News | Lisata Therapeutics Receives U.S. FDA Orphan Drug Designation Granted To LSTA1 For Osteosarcoma

Moomoo 24/7Apr 9 08:41 ET

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Lisata Therapeutics, Inc. (Nasdaq: LSTA) today announced that the U.S. Food and Drug Administration (the "FDA") has granted Orphan Drug Designation ("ODD") to LSTA1, the Company's lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults.

GlobeNewswireApr 9 08:30 ET

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies

Lisata TherapeuticsApr 3 00:00 ET

Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma

Yahoo FinanceMar 22 12:25 ET

Sector Update: Health Care Stocks Higher in Afternoon Trading

Health care stocks rose Thursday afternoon with the NYSE Health Care Index up 0.3% and the Health Care Select Sector SPDR Fund (XLV) gaining 0.4%. The iShares Biotechnology ETF (IBB) added 1.1%. In co

MT NewswiresMar 21 13:52 ET

Lisata Gets FDA Rare Pediatric Disease Status for Lead Drug

Seeking AlphaMar 21 11:30 ET

Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted To LSTA1 For Treatment Of Osteosarcoma

Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted To LSTA1 For Treatment Of Osteosarcoma

BenzingaMar 21 08:02 ET

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Lisata Therapeutics, Inc. (Nasdaq: LSTA) today announced that the U.S. Food and Drug Administration (the "FDA") has granted Rare Pediatric Disease Designation ("RPDD") to LSTA1, the Company's lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in children, adolescents and young adults.

GlobeNewswireMar 21 08:00 ET

Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation

Yahoo FinanceMar 15 07:37 ET

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Yahoo FinanceMar 8 08:35 ET

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

Yahoo FinanceMar 5 08:35 ET